

Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference

SAN DIEGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will present an overview of the company's programs at the Rodman & Renshaw 16th Annual Global Investment Conference at New York Palace Hotel on Tuesday, September 9, 2014 at 2:30pm EDT in New York, NY.

A live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the Company's website at <u>www.fatetherapeutics.com</u>. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells, including small molecules and therapeutic proteins, to treat orphan diseases. The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic disorders, and a muscle satellite stem cell modulation platform, which seeks to activate the regenerative capacity of muscle for treating patients with

degenerative muscle disorders. The Company is presently advancing its lead HSC product candidate, PROHEMA[®], in Phase 2 clinical development for hematologic malignancies, while also advancing its proprietary Wnt7a protein analogs in preclinical development for the treatment of muscular dystrophies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit <u>www.fatetherapeutics.com</u>.

CONTACT: Renee Leck, Stern Investor Relations, Inc.

212.362.1200, renee@sternir.com